Do current therapeutic anti-Aß antibodies for Alzheimer's disease engage the target?

Watt, Andrew D; Crespi, Gabriela A N; Down, Russell A; Ascher, David B; Gunn, Adam; Perez, Keyla A; McLean, Catriona A; Villemagne, Victor L; Parker, Michael W; Barnham, Kevin J; Miles, Luke A

Watt, Andrew D; Crespi, Gabriela A N; Down, Russell A; Ascher, David B; Gunn, Adam; Perez, Keyla A; McLean, Catriona A; Villemagne, Victor L; Parker, Michael W; Barnham, Kevin J; Miles, Luke A.

Affiliation

Watt AD; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, VIC, 3010, Australia.

Acta Neuropathol ; 127(6): 803-10, 2014.

Article in En | MEDLINE | ID: mdl-24803227

Subject(s)

Alzheimer Disease/drug therapy; Amyloid beta-Peptides/metabolism; Antibodies/metabolism; Nootropic Agents/pharmacology; Alzheimer Disease/metabolism; Animals; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal, Humanized/pharmacology; Brain/drug effects; Brain/metabolism; Female; Humans; Mice, Transgenic; Surface Plasmon Resonance

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Amyloid beta-Peptides / Nootropic Agents / Alzheimer Disease / Antibodies Limits: Animals / Female / Humans Language: En Journal: Acta Neuropathol Year: 2014 Type: Article Affiliation country: Australia

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google